About Us

At gmp-orphan, we are driven to find innovative solutions for the unmet needs of patients with rare diseases

Who We Are.

At gmp-orphan (GMPO), it is our mission to identify, develop and provide access to innovative treatments to patients with rare diseases. Our experienced pharmaceutical development and commercial team in the field of rare diseases is critical in advancing this mission.

gmp-orphan (GMPO) was founded in 2011 and the company’s most advanced product candidate is Cuprior for the treatment of Wilson Disease. Find Out More

GMPO Executive team

Naseem Amin Chief Executive Officer and Director
Michel Andraud Chief Financial Officer
Serena Baldissera Head of Global Regulatory & Compliance

Deirdre Kraimer Head of Clinical Operations
Timothy Morley Head of Scientific & Medical Affairs
Catherine Thompson Head of Program Management

GMPO Board of Directors

Alain Huriez Chairman of the Board
Naseem Amin Chief Executive Officer and Director
Chahra Louafi Non Executive Director

Shahzad Malik Non Executive Director
Fred Marin Founder and Non Executive Director
Jean-Francois Morin Board Observer

Investors

gmp-orphan (GMPO) is proud to be supported by a group of leading investors whose shared vision to create a business that delivers medicines of exceptional benefit to patients in areas of high unmet need.

Get In Touch

Find out more about GMPO, who we are and what we do.